SecBot SecBot
SECBOTREPLAY Home › Report › PDSB

PDSB · PDS Biotechnology updated its corporate presentation deck, which…

PDS Biotechnology Corp · 8-K filed Apr 24, 2026 at 16:05 ET

At the news

BULLISHIMPACT 6/10

8-K filed Apr 24, 2026 at 16:05 ET

PDS Biotechnology updated its corporate presentation deck, which includes positive clinical trial data for its lead compound PDS0101 in combination with pembrolizumab for HPV16-positive recurrent/metastatic head and neck cancer. The presentation highlights a median overall survival of 39.3 months and a 77.4% disease control rate, which is significantly better than the 12-18 month benchmark with current standard of care.

  • PDS Biotechnology updated its corporate presentation deck on April 24, 2026
  • The presentation highlights clinical data for PDS0101 in combination with pembrolizumab for HPV16-positive recurrent/metastatic head and neck cancer
  • The trial showed a median overall survival of 39.3 months, compared to a 12-18 month benchmark with current standard of care
  • The disease control rate was 77.4%

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access